Key Points
- Director Medina Manuel Hidalgo sold 1,250 shares of Guardant Health on Dec. 8 at an average price of $105, totaling $131,250 and leaving him with 797 shares (a 61.06% decrease in his stake).
- This sale follows prior disposals by the same director — 1,500 shares on Nov. 7 at $95.19 and 2,165 shares on Sept. 12 at $54.16 — signaling multiple recent insider sales.
- Stock and analyst context: GH trades near its 12‑month high ($112.43) with a $13.06B market cap; analysts hold a consensus "Moderate Buy" with an average price target of $80.86 while several firms have raised targets and given buy/overweight ratings.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,250 shares of the stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $105.00, for a total value of $131,250.00. Following the transaction, the director owned 797 shares of the company's stock, valued at approximately $83,685. The trade was a 61.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Medina Manuel Hidalgo also recently made the following trade(s):
- On Friday, November 7th, Medina Manuel Hidalgo sold 1,500 shares of Guardant Health stock. The shares were sold at an average price of $95.19, for a total value of $142,785.00.
- On Friday, September 12th, Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock. The stock was sold at an average price of $54.16, for a total value of $117,256.40.
Guardant Health Stock Up 0.4%
NASDAQ GH opened at $103.60 on Thursday. Guardant Health, Inc. has a 12-month low of $29.91 and a 12-month high of $112.43. The company has a market capitalization of $13.06 billion, a PE ratio of -32.42 and a beta of 1.58. The firm's 50 day moving average is $87.13 and its 200-day moving average is $64.63.
Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.09. During the same quarter in the prior year, the company posted ($0.88) earnings per share. Guardant Health's revenue for the quarter was up 38.5% on a year-over-year basis. As a group, sell-side analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers acquired a new stake in Guardant Health during the 1st quarter valued at $211,000. PNC Financial Services Group Inc. raised its position in shares of Guardant Health by 25.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,638 shares of the company's stock valued at $112,000 after purchasing an additional 537 shares during the period. Invesco Ltd. raised its position in shares of Guardant Health by 100.9% in the first quarter. Invesco Ltd. now owns 2,794,667 shares of the company's stock valued at $119,053,000 after purchasing an additional 1,403,670 shares during the period. Nuveen LLC acquired a new stake in shares of Guardant Health during the 1st quarter worth about $3,151,000. Finally, HighTower Advisors LLC boosted its holdings in shares of Guardant Health by 0.9% during the 1st quarter. HighTower Advisors LLC now owns 51,107 shares of the company's stock worth $2,177,000 after buying an additional 469 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
GH has been the topic of several analyst reports. Mizuho set a $100.00 target price on Guardant Health in a report on Thursday, October 30th. UBS Group boosted their price target on Guardant Health from $80.00 to $110.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. William Blair reissued an "outperform" rating on shares of Guardant Health in a report on Thursday, September 25th. Barclays raised their target price on shares of Guardant Health from $70.00 to $85.00 and gave the company an "overweight" rating in a research note on Thursday, October 30th. Finally, Morgan Stanley upped their price target on shares of Guardant Health from $105.00 to $130.00 and gave the stock an "overweight" rating in a research report on Monday, December 1st. Twenty-three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Guardant Health currently has a consensus rating of "Moderate Buy" and a consensus price target of $80.86.
Get Our Latest Research Report on GH
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
